SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.98+1.1%Nov 5 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Lance Bredvold1/6/2023 8:00:18 PM
  Read Replies (1) of 52153
 
I appears investors are becoming excited by pamrevlumab at FGEN. Up 23% last two days. 30% over the last 7 trading days. But still only about 50% of it's 150 week moving average 2 years ago at about $20.

And while posting, I might as well mention the hopes of Prothena (PRTA) investors which seem to be jacked up by approval of Aduhelm and other activity in Alzheimers. I've maintained an interest in this company since the 1980's as ELAN and it's long involvement with possible drugs for ALZ. Mostly Ameloid plaque orientation earlier and now also Tau. But the management is also beginning to position themselves as a pharma company with the goal of many products. PRTA also is issueing more shares at $56.50 right now--taking advantage of the huge stock price rise from about $27 in August of 2022.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News